Marina Zafrilla-López, Miriam Acosta-Díez, Marina Mitjans, Anna Giménez-Palomo, Pilar A Saiz, Carme Barrot-Feixat, Ester Jiménez, Sergi Papiol, Victoria Ruiz, Patrícia Gavín, María Paz García-Portilla, Leticia González-Blanco, Julio Bobes, Thomas G Schulze, Eduard Vieta, Antoni Benabarre, Bárbara Arias
Lithium (Li) is the first-line treatment for bipolar disorder (BD) even though only 30 % of BD patients are considered excellent responders. The mechanisms by which Li exerts its action are not clearly understood, but it has been suggested that specific epigenetic mechanisms, such as methylation processes, may play a role. In this regard, DNA methylation patterns can be used to estimate epigenetic age (EpiAge), which is accelerated in BD patients and reversed by Li treatment. Our first aim was to compare the DNA methylation profile in peripheral blood between BD patients categorized as excellent responders to Li (Ex-Rp) and non-responders (N-Rp)...
April 25, 2024: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology